Literature DB >> 6366573

Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid.

V Mehra, P J Brennan, E Rada, J Convit, B R Bloom.   

Abstract

Leprosy remains a significant medical and social problem in many developing countries. The varied forms of the disease form a spectrum. At one pole, tuberculoid leprosy, patients develop high levels of cell-mediated immunity which results in the killing and clearing of bacilli in the tissues. At the lepromatous pole, patients exhibit a selective immunological unresponsiveness to antigens of Mycobacterium leprae so that the organisms inexorably multiply in the skin. We have suggested that in lepromatous leprosy one or a small number of unique antigenic determinants present on M. leprae might induce specific suppressor cells that inhibit the reactivity of helper T-cell clones capable of recognizing other specific or cross reactive determinants. Although unique epitopes have been identified by monoclonal antibodies on a small number of M. leprae proteins, the only unique species of antigen present in M. leprae, and not on any other species of mycobacteria so far examined, is a phenolic glycolipid (gly-I). We show here that this unique antigen of M. leprae is capable of inducing suppression of mitogenic responses of lepromatous patients' lymphocytes in vitro and provide evidence that the suppressor T cells recognize the specific terminal trisaccharide moiety.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6366573     DOI: 10.1038/308194a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  64 in total

1.  Modified lymphocyte response to mitogens induced by the lipopeptide fragment derived from Mycobacterium avium serovar-specific glycopeptidolipids.

Authors:  S K Tassell; M Pourshafie; E L Wright; M G Richmond; W W Barrow
Journal:  Infect Immun       Date:  1992-02       Impact factor: 3.441

2.  Characterization of cellular immune response to chemically defined glycoconjugates from Leishmania mexicana subsp. amazonensis.

Authors:  M M Rodrigues; M T Xavier; L M Previato; M A Barcinski
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

Review 3.  New aspects of vaccine development.

Authors:  F Y Liew
Journal:  Clin Exp Immunol       Date:  1985-11       Impact factor: 4.330

4.  Serum IL-2 inhibitor in mice. I. Increase during infection.

Authors:  R Lelchuk; J H Playfair
Journal:  Immunology       Date:  1985-09       Impact factor: 7.397

5.  A non-specific inhibitor produced by Candida albicans activated T cells impairs cell proliferation by inhibiting interleukin-1 production.

Authors:  G Lombardi; D Vismara; E Piccolella; V Colizzi; G L Asherson
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

6.  Phenolic glycolipid 1 of Mycobacterium leprae causes nonspecific inflammation but has no effect on cell-mediated responses in mice.

Authors:  S J Brett; C Lowe; S N Payne; P Draper
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

7.  Genetics of Capsular Polysaccharides and Cell Envelope (Glyco)lipids.

Authors:  Mamadou Daffé; Dean C Crick; Mary Jackson
Journal:  Microbiol Spectr       Date:  2014

8.  In vitro suppression of interleukin 2 production by Mycobacterium leprae antigen.

Authors:  S Makonkawkeyoon; W Kasinrerk
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

9.  Targeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides.

Authors:  A K Azad; T D Sirakova; L M Rogers; P E Kolattukudy
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

10.  Induction of delayed-type hypersensitivity in human volunteers immunized with a candidate leprosy vaccine consisting of killed Mycobacterium leprae.

Authors:  H K Gill; A S Mustafa; T Godal
Journal:  Bull World Health Organ       Date:  1986       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.